Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03088540 · OUTCOME

Best Overall Response (BOR) Per IRC

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 73.5 months

What was measured

BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

Analysis population: FAS included all randomized participants.

Groups in this outcome

Cemiplimab

Participants received cemiplimab monotherapy

Chemotherapy

Participants received platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cemiplimab357
Chemotherapy355

Reported measurements

Source class 1

Complete Response (CR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab30Not reportedNot reportedNot reportedNot reported
Chemotherapy4Not reportedNot reportedNot reportedNot reported

Partial Response (PR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab121Not reportedNot reportedNot reportedNot reported
Chemotherapy72Not reportedNot reportedNot reportedNot reported

Stable Disease (SD)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab90Not reportedNot reportedNot reportedNot reported
Chemotherapy175Not reportedNot reportedNot reportedNot reported

Non-CR/Non-PD

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab2Not reportedNot reportedNot reportedNot reported
Chemotherapy4Not reportedNot reportedNot reportedNot reported

Progressive Disease (PD)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab76Not reportedNot reportedNot reportedNot reported
Chemotherapy56Not reportedNot reportedNot reportedNot reported

Not Evaluable (NE)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cemiplimab38Not reportedNot reportedNot reportedNot reported
Chemotherapy44Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        30
      2. group Id
        OG001
        value
        4
      title
      Complete Response (CR)
    2. measurements
      1. group Id
        OG000
        value
        121
      2. group Id
        OG001
        value
        72
      title
      Partial Response (PR)
    3. measurements
      1. group Id
        OG000
        value
        90
      2. group Id
        OG001
        value
        175
      title
      Stable Disease (SD)
    4. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        4
      title
      Non-CR/Non-PD
    5. measurements
      1. group Id
        OG000
        value
        76
      2. group Id
        OG001
        value
        56
      title
      Progressive Disease (PD)
    6. measurements
      1. group Id
        OG000
        value
        38
      2. group Id
        OG001
        value
        44
      title
      Not Evaluable (NE)
denoms
  1. counts
    1. group Id
      OG000
      value
      357
    2. group Id
      OG001
      value
      355
    units
    Participants
description
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
groups
  1. description
    Participants received cemiplimab monotherapy
    id
    OG000
    title
    Cemiplimab
  2. description
    Participants received platinum-based doublet chemotherapy
    id
    OG001
    title
    Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
FAS included all randomized participants.
reporting Status
POSTED
time Frame
Up to 73.5 months
title
Best Overall Response (BOR) Per IRC
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice